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A B S T R A C TObjectives: Clinicians and payers require rapid comparative effective-
ness (CE) evidence generation to inform decisions for new drugs. We
empirically assessed treatment dynamics of newly marked drugs and
their implications for conducting CE research. Methods: We used
claims data to evaluate ﬁve drug-outcome pairs: 1) raloxifene (vs.
alendronate) and fracture; 2) risedronate (vs. alendronate) and fracture;
3) simvastatin plus ezetimibe ﬁxed-dose combination (simvastatin þ
ezetimibe) (vs. simvastatin alone) and cardiovascular events; 4) rofecoxib
(vs. nonselective nonsteroidal anti-inﬂammatory drugs [ns-NSAIDs])
and myocardial infarction; and 5) rofecoxib (vs. ns-NSAIDS) and gastro-
intestinal bleed. We examined utilization dynamics in the early market-
ing period, including evolving utilization patterns, outcome risk among
those treated with new versus established drugs, and prior treatment
patterns that may indicate treatment resistance or intolerance. We
addressed these challenges by replicating active CE monitoring with
sequential matched cohort analysis. Results: Patients initiating newsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.05.008
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ondence to: Joshua J. Gagne, Division of Pharmaco
n’s Hospital and Harvard Medical School, 1620 Trdrugs were more likely to have used other drugs for the same indication
in the past, but the majority of patients in all new drug cohorts were
treatment naive (82.0% overall). Patients initiating rofecoxib had higher
predicted baseline risk of gastrointestinal bleed than did patients
initiating ns-NSAIDs. Patients initiating risedronate and alendronate
had similar predicted baseline risks of fracture, while those initiating
raloxifene and simvastatin þ ezetimibe had lower risks of outcomes of
interest relative to their comparators. Prospective monitoring yielded
results consistent with expectation for each example. Conclusions:
Many challenges to assessing the CE of new drugs are borne out in
empirical data. Attention to these challenges can yield valid CE results.
Keywords: effectiveness, new drugs, prospective monitoring, validity.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Optimizing patient-centered outcomes requires more than knowing
whether a medication works better than placebo in highly proto-
colized clinical trial settings [1]. At the time of approval, however,
few new drugs have been compared with active alternatives [2] and
among those that have, a limited set of alternatives is used even
when many potential treatment options exist [3]. Patients, clini-
cians, and payers therefore do not have all the evidence required for
fully informed treatment decisions involving new drugs.
Several mechanisms exist to generate comparative effective-
ness (CE) evidence in the early marketing period, but they carry
important limitations. Large head-to-head trials of multiple drugs
tend to be costly and require many years to complete. The
generalizability of results of open-label extensions of phase III
trials and indirect comparisons or network meta-analyses of
efﬁcacy trials [4] are limited to populations enrolled in thepreapproval trials [5], which do not tend to reﬂect populations
of patients that use the drugs in the postmarketing setting [6–8].
Once approved, new drugs are often consumed by many
thousands of patients despite the lack of evidence of so-called
real-world effectiveness. Patients’ prescription-ﬁlling histories and
health care encounters are captured in near real time in payers’
and providers’ electronic health care databases. Analyzing these
data as they accrue offers great potential for providing continuous
information support for decision makers and other stakeholders in
a “learning health care system” [9]. These data can provide in-the-
moment insight into the comparative effectiveness and safety of
new drugs as experience with the products grows [10,11], which
could form the basis of coverage with evidence development
strategies, including risk-sharing arrangements [12], and are being
used in the US Food and Drug Administration’s Sentinel Initiative
to assess the safety of newly approved drugs [13]. Using observa-
tional data to determine the comparative effectiveness of newociety for Pharmacoeconomics and Outcomes Research (ISPOR).
epidemiology and Pharmacoeconomics, Department of Medicine,
emont Street, Suite 3030, Boston, MA 02120, USA.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 5 4 – 1 0 6 2 1055drugs in the early marketing period is challenging [5,11]. In
particular, selective prescribing of new drugs may lead to con-
founding by indication and patients initiating a new drug may be
more likely to have failed a prior treatment [5].
By using data covering the early marketing periods of four
example drugs (rofecoxib, raloxifene, risedronate, and ﬁxed-dose
simvastatin plus ezetimibe combination), we empirically eval-
uated aspects of treatment dynamics in the early marketing period
that can give rise to confounding in observational comparative
effectiveness studies. Speciﬁcally, we sought to examine 1) the
utilization trends of newly marketed drugs, 2) whether users of
new drugs are “sicker” than users of more established therapies, 3)
whether users of new drugs are more likely to have failed prior
treatments, and 4) whether it is possible to ﬁnd patients initiating
alternative drugs who are comparable to patients initiating the
new drugs. We then applied a recently proposed ensemble of
methods to emulate active monitoring beginning at market
authorization of each drug of interest [5,14,15] and assessed
whether the approach addressed these sources of confounding.Methods
Data
We used 12 years (1994–2005) of medical and pharmacy claims
data from Medicare beneﬁciaries in New Jersey and Pennsylvania
who were enrolled in pharmaceutical assistance programs in
these states (the Pharmacy Assistance for the Aged and Disabled
[PAAD] in New Jersey and the Pharmacy Assistance Contract for
the Elderly [PACE] in Pennsylvania). Both PAAD and PACE provide
medications with no formulary restrictions and at minimal
expense to elderly individuals with low income but who do not
meet the Medicaid annual income threshold. PACE and PAAD
data are linked to Medicare Parts A and B data.
Patients
We identiﬁed initiators of four drugs of interest beginning at their
market authorization and initiators of an active comparator drug or
class for each: 1) rofecoxib versus nonselective nonsteroidal anti-
inﬂammatory drugs (ns-NSAIDs), 2) raloxifene versus alendronate,
3) risedronate versus alendronate, and 4) simvastatin plus ezeti-
mibe ﬁxed-dose combination (Vytorin; simvastatin þ ezetimibe)
versus simvastatin alone. Each pair was chosen to create a set of
examples with new drugs that represent slightly different types of
advances on the comparator. For example, rofecoxib offered a more
selective mechanism of action over ns-NSAIDs; raloxifene offers a
different mechanism of action than does alendronate; risedronate
is a follow-on product in the same class as alendronate; and
simvastatin plus ezetimibe is a combination product containing
an established therapy and is thought to be more effective for some
patients, though conclusive evidence is lacking. Pairs were also
selected to ensure that the comparator had been available for some
time prior to the authorization of the new drug.
Outcomes
Our outcomes of interest were myocardial infarction (MI) and
gastrointestinal (GI) bleeding for the rofecoxib versus ns-NSAIDs
example, a composite fracture end point for the raloxifene versus
alendronate and risedronate versus alendronate examples, and a
composite cardiovascular event end point for the simvastatin plus
ezetimibe ﬁxed-dose combination versus simvastatin alone. The
composite fracture outcome involved fractures at the hip, humerus,
pelvis, and radius, and the cardiovascular event outcome com-
prised MI, cerebrovascular events (i.e., ischemic and hemorrhagic
stroke), and acute coronary syndromes with revascularization. Wedeﬁned all outcomes by using claims-based algorithms. Validation
studies comparing the algorithms to medical chart reviews have
found positive predictive values of 94% for MI [16], 88% for GI bleeds
[17], 86% for cerebrovascular events [18], and between 93% and 98%
for each fracture outcome [19,20].
For each example, we followed patients for the outcome(s) of
interest by using an intention-to-treat approach beginning the
day after the initiation of their index drug and for a maximum of
180 days. We censored patients at the ﬁrst of the following
events: 1) occurrence of the outcome of interest, 2) death, or 3)
end of study period (December 31, 2005).
Analysis
We examined trends in utilization by plotting the number of
initiators of the new drugs, the comparators, and similar drugs in
each calendar quarter starting 1 year before the new drugs’ market
authorization. We deﬁned initiators as those patients with no prior
use of the index drug in the preceding 180 days [21]. We charac-
terized prior treatment patterns by calculating the proportion of
patients initiating the new drugs and their respective comparators
who had exposure to other drugs used to treat the same condition
in the 180 days before index drug initiation. Speciﬁcally, we
calculated the proportion of patients in the new drug group who
had used the comparator and vice versa, the proportion of patients
in each group who had used various alternatives (e.g., celecoxib and
valdecoxib for the rofecoxib example, other statins for the simvas-
tatin þ ezetimibe example, and other bisphosphonates or calcito-
nin for the raloxifene and risedronate examples), and the
proportion of patients in each group who were treatment naive.
We tabulated demographic and clinical characteristics of
patients initiating the new drugs in the very early marketing
period (i.e., the ﬁrst 6 months following market authorization) and
compared the characteristics to those initiating the active com-
parator during the same time. We identiﬁed a large number of
predeﬁned covariates for each example, including patient demo-
graphics (e.g., age, gender, and race), health service utilization
variables (e.g., number of physician visits, number of hospital-
izations, number of unique drugs dispensed, and a comorbidity
score that combines the Charlson and Elixhauser indices [22]), and
speciﬁc risk factors for the outcome(s) of interest in each example.
All covariates were ascertained during the 180 days preceding the
index prescription date and are listed in the Appendix Tables in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2013.05.008. To compare the baseline risk of the outcomes of
interest between treatment groups, we estimated a disease risk
score, deﬁned as a patient’s likelihood of experiencing the out
come of interest conditional on baseline covariates [23–26]. Follow
ing the approach of Glynn et al. [26], we developed the disease risk
score model for each example among patients exposed to the
comparator drug prior to the market authorization of the new
drug. We then applied the resulting model coefﬁcients in the form
of a prediction rule to all patients in both treatment groups after
the introduction of the new drug. We considered all predeﬁned
covariates listed in the Appendix Tables in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.05.008.
Finally, we replicated prospective comparative effectiveness
monitoring by analyzing each example as if new data became
available on a quarterly basis following the introduction of each
new drug. We updated estimates of effect over time as experience
with the new drug grows [14,15,27]. We divided the databases
into sequential data sets deﬁned by claims occurring in each
calendar quarter. For each example, patients who initiated the
new drug of interest within 6 months of its market authorization
formed monitoring period one. Subsequent monitoring periods
were deﬁned by 3-month intervals. We 1:1 matched initiators of
the new drug in each monitoring period to initiators of the
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a traditional propensity score (PS) and a high-dimensional PS (hd-
PS). PSs are summary scores that reduce the dimensionality of
confounding by combining potential confounders into a single
scalar variable [28]. The hd-PS is a semi-automated algorithm
that identiﬁes and selects for inclusion in the PS model a large
number of variables that behave like confounders based on
empirical associations with the exposure and outcome of interest
[29]. While not necessarily structural confounders, these empiri-
cally identiﬁed variables may act as confounders because of
chance imbalances with the exposure and outcome of interest
in the database. The traditional PS model included all baseline
covariates listed in the Appendix Tables in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.05.008.
The hd-PS model included all variables in the Appendix along
with the empirically identiﬁed covariates [29]. We estimated both
hazard ratios and cumulative incidence differences (i.e., risk
differences) to compare event frequencies between treatment
groups. We reestimated the effect estimates and their 95%
conﬁdence interval after adding each sequential data set for each
monitoring period.Results
Among Medicare beneﬁciaries in New Jersey and Pennsylvania, we
identiﬁed 65,370 initiators of rofecoxib between the second quarter
of 1999 and the third quarter of 2004, 13,173 initiators of raloxifene
between 1998 and the end of 2005, 23,341 initiators of risedronate
between the second quarter of 2000 and the end of 2005, and 8,288
initiators of the simvastatin þ ezetimibe combination between the
third quarter of 2002 and the end of 2005 (Table 1).Utilization
Rofecoxib was rapidly taken up in the early marketing period,
reaching a peak in the second quarter of 2000 (Fig. 1). The number
of new users per quarter decreased thereafter until 2004 when
the drug was withdrawn from the market. Raloxifene exhibited a
similar pattern, with an initial rapid uptake followed by a period
of stabilization and subsequent decline (Fig. 2). The erosion in
raloxifene use appeared to correspond to the introduction and
increased use of risedronate. We also observed a period of rapid
uptake and stabilization of risedronate, but this was followed by
continued growth corresponding to the approval of a once-
weekly formulation in 2002 (Fig. 2). A similar uptick was observedTable 1 – Patterns of use of drugs for the same indication
new drugs and their comparators.
Total no. of
initiators
Prior use of dru
in other compar
group, n (% of t
Rofecoxib 65,370 6,107 (9.3)
ns-NSAIDs 96,259 1,146 (1.2)
Raloxifene 13,173 499 (3.8)
Alendronate 62,699 403 (0.6)
Risedronate 23,341 1,189 (5.1)
Alendronate 45,075 202 (0.5)
Simvastatin þ ezetimibe 8,228 3,310 (40.2)
Simvastatin alone 14,590 409 (2.8)
ns-NSAIDs, nonselective nonsteroidal anti-inﬂammatory drugs.with alendronate when the once-weekly formulations were
approved at the end of 2000.
Prior Treatment Patterns
As compared to patients initiating the more established therapies,
patients initiating the new drugs were more likely to have been
previously exposed to drugs in the other comparison groups
(Table 1). This was most pronounced among patients initiating
the simvastatin þ ezetimibe combination where 40% had been
exposed to simvastatin alone in the prior 180 days as compared
with 3% of patients initiating simvastatin alone with prior use of
the simvastatin þ ezetimibe combination. Among patients who
initiated rofecoxib, 9% had had prior exposure to ns-NSAIDs versus
1% of patients initiating ns-NSAIDs with prior rofecoxib exposure.
Patients initiating the new drugs were also more likely to have
been exposed to other drugs for the same indication in the prior
180 days. Among patients initiating rofecoxib, 17% had had a
prescription for celecoxib or valdecoxib in the preceding 180 days
versus 13% of patients among the ns-NSAID group. As a result,
fewer patients in the new drug group were treatment naive as
compared to patients in the active comparator groups. In all
instances except the simvastatin þ ezetimibe example, greater
than 70% of new drug initiators were treatment naive in the 180
days prior to index drug initiation.
Differences in Patient Characteristics and Baseline Risk
In general, patients initiating rofecoxib exhibited signs of being
sicker or at higher risk of outcomes of interest (Fig. 3) and had
higher predicted baseline probabilities of both GI bleed and MI
within 6 months as compared to patients initiating ns-NSAIDs
(Fig. 4). Patients initiating risedronate and alendronate were nearly
identical on patient characteristics and baseline risk factors (Figs. 3
and 4). Patients initiating raloxifene and simvastatin þ ezetimibe
were generally healthier and had lower predicted baseline
probabilities of outcomes of interest than did patients initiating
alendronate and simvastatin alone, respectively (Figs. 3 and 4).
Differences in predicted baseline probabilities of outcomes between
treatment groups did not materially change across periods for each
example. Despite differences in baseline risk factors and predicted
outcome probabilities, we were able to ﬁnd hd-PS matches for the
majority of treatment-naive patients in each period for each
example (see the Appendix Figure in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2013.05.008). hd-PS matching
made the treatment groups more similar on baseline risk of each
outcome (Fig. 4).in the 180 days prior to the initiation of each of four
g(s)
ison
otal)
Prior use of other drugs
for same indication,
n (% of total)
Treatment naive,
n (% of total)
11,347 (17.4) 45,932 (70.3)
12,789 (13.3) 81,788 (85.0)
1,414 (10.7) 11,160 (84.7)
5,402 (8.6) 56,755 (90.5)
2,668 (11.4) 19,239 (82.4)
4,193 (9.3) 40,527 (89.9)
2,107 (25.6) 2,811 (34.2)
2,941 (20.2) 11,240 (77.0)
Fig. 1 – Utilization of nonsteroidal anti-inﬂammatory medications among Medicare beneﬁciaries in two US states (1998–2005).
Dotted vertical lines indicate the ﬁrst quarter in which prescriptions for each drug appeared in the database. ns-NSAIDs,
nonselective nonsteroidal anti-inﬂammatory drugs.
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Figure 5 demonstrates the results of the rofecoxib versus ns-
NSAID comparison on both MI and GI bleed outcomes, replicating
sequential analyses as if the data accrued prospectively, using an
hd-PS–matched sequential incident user cohort approach. Over-
all, as compared to ns-NSAIDS, rofecoxib was associated with a
lower rate of GI bleed (6-month risk difference −0.00082; 95%
conﬁdence interval −0.00232 to 0.00069; corresponding to 8 fewer
GI bleed events for every 10,000 patients treated with rofecoxib
instead of ns-NSAIDs) and a higher rate of MI (6-month risk
difference 0.00229; 95% conﬁdence interval 0.00019–0.00438; cor-
responding to 23 excess MIs for every 10,000 patients treated with
rofecoxib instead of ns-NSAIDs). The direction and magnitude of
these results became evident during the monitoring process
several years before the last period. Although the crude estimate
for GI bleed was elevated among rofecoxib initiators (Fig. 6),
reﬂecting the underlying confounding by higher risk status, theFig. 2 – Utilization of alendronate, raloxifene, and risedronate a
Dotted vertical lines indicate the ﬁrst quarter in which prescriptfully adjusted results suggest a protective effect of the drug,
consistent with expectation.
In unadjusted analyses, we also observed lower rates of
outcomes among raloxifene and simvastatin þ ezetimibe initia-
tors, reﬂecting confounding made apparent by the large differ-
ences in baseline outcome risks (Fig. 6). After hd-PS matching we
observed no difference in fracture rates among patients treated
with raloxifene versus alendronate and no differences in car-
diovascular event rates among patients treated with simvastatin
þ ezetimibe versus simvastatin alone. Neither PS matching nor
hd-PS matching materially changed the effect estimate for
risedronate because this association was not very confounded.Discussion
Observational studies of treatment effects are vulnerable to
various biases, particularly when conducted for new drugs shortlymong Medicare beneﬁciaries in two US states (1997–2005).
ions for each drug appeared in the database.
Fig. 3 – Balance in key baseline characteristics prior to matching among initiators in the ﬁrst 6 months following each new
drug’s market authorization. CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ns-NSAIDs,
nonselective nonsteroidal anti-inﬂammatory drugs.
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or intended outcomes, and when using claims data that are not
collected for research purposes. Across four examples we found
that the utilization of new drugs does not follow a predictable
pattern, that new drug initiators are more likely to have been
exposed to other drugs that can be used to treat the same
indication, and that new drug initiators can differ with respect
to important confounders and baseline outcome risk from
patients initiating more established therapies. These dynamics
can pose threats to observational studies aimed at generating
comparative effectiveness and safety information in the early
marketing phase. However, an hd-PS–matched incident user
cohort design can overcome many of these challenges to produce
valid and transparent comparative effectiveness evidence as
experience with the new drugs grows in near real time, providing
continuous decision-support information. Despite the many dif-
ferences in initiators of new drugs versus the more established
therapies, we were able to identify adequate matches for the
majority of new drug initiators, even in the time immediately
following market authorization. The approach may be particularly
useful for monitoring prespeciﬁed drug-outcome pairs in routine
surveillance activities, including the US Food and Drug Admin-
istration’s developing Sentinel System [13–15,27,30].
Confounding is a key threat to generating valid comparative
evidence from observational data, particularly for anticipated and
intended outcomes for which prognoses are incorporated into the
treatment selection decision. Patients initiating rofecoxib had a
higher average baseline risk of GI bleed than did patients initiating
ns-NSAIDs, reﬂecting the preferential prescribing of cyclooxyge-
nase inhibitors to those at risk for gastrotoxicity. PS matching and
hd-PS matching moved the unadjusted estimate of GI bleeding risk
in the direction consistent with what has been observed in
randomized trials [31]. Differences in the predicted risk of MI,
which likely would not have been anticipated at the time of
prescribing, were less pronounced, though rofecoxib patients were
slightly older than ns-NSAID patients and age is a strong risk factor
for MI. PS matching and hd-PS matching enabled us to examine
multiple outcomes among the same matched cohorts while
simultaneously adjusting for confounding of both associations.Predicted baseline risks of fracture among patients initiating
risedronate versus alendronate were nearly identical, reﬂecting
very similar use of drugs that are perceived to be similar and
demonstrating the value of a well-selected active comparator.
Comparing drugs that share similar treatment selection proc-
esses can greatly reduce the potential for confounding [10].
Patients initiating raloxifene and simvastatin þ ezetimibe had
lower predicted probabilities of outcomes at baseline relative to
patients initiating their comparators. These differences were
removed by PS matching and, even more so, by hd-PS matching.
Patients initiating a new drug instead of a more established
therapy may be more likely to have tried other drugs for the same
indication but have failed on them or not tolerated them well.
Indeed, we observed that patients initiating a new drug were more
likely to have experience with other drugs for the same indication.
However, the majority of patients initiating each of the new drugs
and their active comparators were treatment naive for that indica-
tion. The exception was the simvastatin þ ezetimibe ﬁxed-dose
combination where many patients had experience with simvasta-
tin, ezetimibe, or both. Nevertheless, we were able to identify
enough patients in each sequential period to enable monitoring
among those who were treatment naive for each example.
By combining various design and analytic features [32], the
hd-PS–matched incident user approach to active monitoring
addresses many of the challenges in assessing the comparative
effectiveness and safety of drugs in the period shortly after their
market authorization. Focusing on incident users, and more
speciﬁcally patients who are treatment naive, overcomes con-
cerns about patients initiating the new drug being more likely to
be resistant or intolerant to treatment and helps ensure that the
analysis answers the most relevant question for decision makers
[33,34]. Using active comparators with as similar indications and
use as possible reduces the degree to which confounding by
indication can bias results. As expected, we observed the best
marginal balance in baseline covariates and predicted baseline
outcome risk between initiators of drugs from the same class. PS
matching and hd-PS matching further enhanced balance on
baseline risk factors and facilitated simultaneous balancing of
predicted baseline risk of multiple outcomes.
Fig. 4 – Baseline predicted probability of each outcome among unmatched and matched cohorts. Each panel displays the
predicted baseline probability of the outcome of interest (disease risk score) among initiators of the new drug (solid line) and
the active comparator (dashed line) in each calendar quarter following introduction of the new drug. Panels on the left are
based on the full cohort, prior to matching, and the panels on the right are after matching on a high-dimensional propensity
score. ns-NSAIDs, nonselective nonsteroidal anti-inﬂammatory drugs.
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Fig. 5 – Replicated prospective monitoring comparing rofecoxib and non-selective non-steroidal anti-inﬂammatory drugs.
Each point represents a risk difference for gastrointestinal bleed (blue) or myocardial infarction (red) among initiators of
rofecoxib matched by high-dimensional propensity score to initiators of nonselective nonsteroidal anti-inﬂammatory drugs.
Risk differences are cumulative in that they are based on all data that had accrued in the database up to and including that
monitoring period. Dotted lines represent the 95% conﬁdence intervals.
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that have been raised about comparing the safety and effective-
ness of newly marketed drugs in observational data, our proposed
approach to active monitoring in this setting appears to mitigate
potential bias related to these concerns. Nevertheless, we eval-
uated only four outcomes, among four new drugs intended to treat
chronic conditions, with three active comparators in two states’
low-income Medicare prescription assistance populations.Fig. 6 – Overall hazard ratios and 95% conﬁdence intervals for e
adjustment. hdPS, high-dimensional propensity score; GI, gastr
nonselective nonsteroidal anti-inﬂammatory drugs; PS, propensTherefore, our ﬁndings may not always generalize to other
examples. In particular, appropriate active comparators may not
be available for some new drugs, especially those that are the ﬁrst
approved for a given indication, which will limit the ability to
address confounding. In addition, the Medicare beneﬁciaries that
we studied received prescription drug coverage through pharma-
ceutical beneﬁts programs that impose few ﬁnancial barriers to
drug access. As such, utilization and channeling of new drugs mayach of ﬁve examples using three levels of confounding
ointestinal bleed; MI, myocardial infarction; ns-NSAIDs,
ity score.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 5 4 – 1 0 6 2 1061differ in other systems, such as when payers require higher co-
payments for new drugs or exclude them entirely from a
formulary.
The limitations of claims data are well described [10,11]. The
data do not include information on whether patients actually
consumed their dispensed medications, on over-the-counter
medication use, or on other clinically important potential con-
founders such as smoking status, physical activity, body mass
index, or indication for drug use, such as bone density and
cholesterol levels. In addition, we compared the results of each
active monitoring example to expectations based on prior evi-
dence and clinical judgment. Large randomized trials, however,
do not exist for each comparison. This further highlights the need
for observational comparative effectiveness research but also
makes it difﬁcult to establish benchmarks. Moreover, clinical
trials and observational studies often include different patient
populations. To the extent that treatment effect heterogeneity
exists among patient subgroups, results of the different study
types may not be comparable even if each is perfectly internally
valid for its speciﬁc population. Nevertheless, after addressing
sources of potential bias, our ﬁve assessments yielded results
consistent with our a priori expectations.
In conclusion, understanding the comparative effectiveness
and safety of new drugs requires an ensemble of data from
multiple sources and various analytic approaches [5]. Observa-
tional studies in electronic health care databases can provide one
important piece of this evidence base, particularly in the early
marketing period of a new drug when data from other sources are
lacking. Analyses that use rigorous design and analytic features
can overcome or reduce threats to validity and provide rapid and
useful information to stakeholders.Acknowledgments
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